Dianthus Therapeutics, Inc. /DE/ Net Income
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Net Income of -$50.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$50.22M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$40.83M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$64.43M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$36.77M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for fiscal 2022 was -$28.48M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for fiscal 2020 was -$74.94M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for fiscal 2019 was -$76.77M.
- Dianthus Therapeutics, Inc. /DE/ net income (loss) attributable to parent for fiscal 2018 was -$57.52M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$50.22M 10-Q · filed 2026-08-04 | -$91.05M 10-Q · filed 2026-08-04 | -$155.48M derived: sum of 3 quarters · filed 2026-08-04 | -$192.25M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$40.83M 10-Q · filed 2026-08-04 | -$105.27M derived: sum of 2 quarters · filed 2026-08-04 | -$142.03M derived: sum of 3 quarters · filed 2026-08-04 | -$173.66M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$64.43M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$101.20M derived: sum of 2 quarters · filed 2026-04-09 | -$132.83M derived: sum of 3 quarters · filed 2026-08-04 | -$162.34M DEF 14A · filed 2026-04-09 | ||||
| 2025-09-30 | -$36.77M 10-Q · filed 2025-11-05 | -$68.39M derived: sum of 2 quarters · filed 2026-08-04 | -$97.91M 10-Q · filed 2025-11-05 | -$126.34M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$31.63M 10-Q · filed 2026-08-04 | -$61.14M 10-Q · filed 2026-08-04 | -$89.58M derived: sum of 3 quarters · filed 2026-08-04 | -$114.75M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$29.51M 10-Q · filed 2026-08-04 | -$57.95M derived: sum of 2 quarters · filed 2026-08-04 | -$83.13M derived: sum of 3 quarters · filed 2026-08-04 | -$100.73M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2024-12-31 | -$28.44M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$53.61M derived: sum of 2 quarters · filed 2026-04-09 | -$71.22M derived: sum of 3 quarters · filed 2026-04-09 | -$84.97M DEF 14A · filed 2026-04-09 | ||||
| 2024-09-30 | -$25.17M 10-Q · filed 2025-11-05 | -$42.78M derived: sum of 2 quarters · filed 2025-11-05 | -$56.53M 10-Q · filed 2025-11-05 | -$67.08M derived: sum of 4 quarters · filed 2026-04-09 | ||||
| 2024-06-30 | -$17.61M 10-Q · filed 2025-11-05 | -$31.36M 10-Q · filed 2025-08-07 | -$41.91M derived: sum of 3 quarters · filed 2026-04-09 | -$56.67M derived: sum of 4 quarters · filed 2026-04-09 | ||||
| 2024-03-31 | -$13.75M 10-Q · filed 2025-11-05 | -$24.30M derived: sum of 2 quarters · filed 2026-04-09 | -$39.06M derived: sum of 3 quarters · filed 2026-04-09 | -$50.20M derived: sum of 4 quarters · filed 2026-04-09 | ||||
| 2023-12-31 | -$10.55M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-09 | -$25.32M derived: sum of 2 quarters · filed 2026-04-09 | -$36.46M derived: sum of 3 quarters · filed 2026-04-09 | -$43.55M DEF 14A · filed 2026-04-09 | -$43.55M 10-K · filed 2024-03-21 | |||
| 2023-09-30 | -$14.76M 10-Q · filed 2024-11-07 | -$25.90M derived: sum of 2 quarters · filed 2024-11-07 | -$32.99M 10-Q · filed 2024-11-07 | -$43.11M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$11.14M 10-Q · filed 2024-11-07 | -$3.28M 10-Q · filed 2023-08-03 | -$18.23M 10-Q · filed 2024-08-08 | -$32.45M 10-Q · filed 2023-08-03 | -$28.34M derived: sum of 3 quarters · filed 2024-11-07 | -$36.13M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$7.09M 10-Q · filed 2024-11-07 | -$29.17M 10-Q · filed 2023-05-15 | -$17.20M derived: sum of 2 quarters · filed 2024-11-07 | -$24.99M derived: sum of 3 quarters · filed 2024-11-07 | -$30.68M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2022-12-31 | -$10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$17.90M derived: sum of 2 quarters · filed 2024-03-21 | -$23.59M derived: sum of 3 quarters · filed 2024-03-21 | -$28.48M 10-K · filed 2024-03-21 | -$76.46M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$7.78M 10-Q · filed 2023-11-09 | -$16.06M 10-Q · filed 2022-11-03 | -$13.48M derived: sum of 2 quarters · filed 2023-11-09 | -$18.36M 10-Q · filed 2023-11-09 | -$56.28M 10-Q · filed 2022-11-03 | $20.38M derived: sum of 4 quarters · filed 2023-12-21 | ||
| 2022-06-30 | -$5.70M 10-Q · filed 2023-11-09 | -$17.27M 10-Q · filed 2022-08-04 | -$40.22M 10-Q · filed 2023-08-03 | $28.16M derived: sum of 3 quarters · filed 2023-12-21 | $10.73M derived: sum of 4 quarters · filed 2023-12-21 | |||
| 2022-03-31 | -$4.88M 10-Q · filed 2023-11-09 | -$22.95M 10-Q · filed 2022-05-16 | $33.85M derived: sum of 2 quarters · filed 2023-12-21 | $16.43M derived: sum of 3 quarters · filed 2023-12-21 | -$501.00K derived: sum of 4 quarters · filed 2023-12-21 | |||
| 2021-12-31 | $38.73M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | $21.31M derived: sum of 2 quarters · filed 2023-12-21 | $4.38M derived: sum of 3 quarters · filed 2023-12-21 | -$13.11M 8-K · filed 2023-12-21 | -$71.14M 10-K · filed 2022-03-08 | |||
| 2021-09-30 | -$17.43M 10-Q · filed 2022-11-03 | -$34.35M derived: sum of 2 quarters · filed 2022-11-03 | -$51.84M 10-Q · filed 2022-11-03 | -$70.01M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$16.93M 10-Q · filed 2022-08-04 | -$34.42M 10-Q · filed 2022-08-04 | -$52.59M derived: sum of 3 quarters · filed 2022-08-04 | -$70.26M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$17.49M 10-Q · filed 2022-05-16 | -$35.66M derived: sum of 2 quarters · filed 2022-05-16 | -$53.34M derived: sum of 3 quarters · filed 2022-05-16 | -$72.41M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$18.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$35.85M derived: sum of 2 quarters · filed 2022-03-08 | -$54.92M derived: sum of 3 quarters · filed 2022-03-08 | -$74.94M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | -$17.68M 10-Q · filed 2021-11-04 | -$36.76M derived: sum of 2 quarters · filed 2021-11-04 | -$56.77M 10-Q · filed 2021-11-04 | -$80.00M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$19.08M 10-Q · filed 2021-08-05 | -$39.09M 10-Q · filed 2021-08-05 | -$62.33M derived: sum of 3 quarters · filed 2021-08-05 | -$83.32M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$20.01M 10-Q · filed 2021-05-06 | -$43.25M derived: sum of 2 quarters · filed 2021-05-06 | -$64.24M derived: sum of 3 quarters · filed 2021-05-06 | -$81.95M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | -$23.24M 10-K · filed 2020-03-03 | -$44.23M derived: sum of 2 quarters · filed 2020-11-05 | -$61.94M derived: sum of 3 quarters · filed 2020-11-05 | -$76.77M 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | -$20.99M 10-Q · filed 2020-11-05 | -$38.70M derived: sum of 2 quarters · filed 2020-11-05 | -$53.53M 10-Q · filed 2020-11-05 | -$70.21M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$17.71M 10-Q · filed 2020-08-06 | -$32.54M 10-Q · filed 2020-08-06 | -$49.22M derived: sum of 3 quarters · filed 2020-08-06 | -$65.24M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | -$14.83M 10-Q · filed 2020-05-07 | -$31.51M derived: sum of 2 quarters · filed 2020-05-07 | -$47.53M derived: sum of 3 quarters · filed 2020-05-07 | -$61.19M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$16.68M 10-K · filed 2020-03-03 | -$32.69M derived: sum of 2 quarters · filed 2020-03-03 | -$46.35M derived: sum of 3 quarters · filed 2020-03-03 | -$57.52M 10-K · filed 2020-03-03 | ||||
| 2018-09-30 | -$16.02M 10-K · filed 2020-03-03 | -$29.68M derived: sum of 2 quarters · filed 2020-03-03 | -$40.84M 10-Q · filed 2019-11-13 | -$48.87M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-06-30 | -$13.66M 10-K · filed 2020-03-03 | -$24.82M 10-Q · filed 2019-08-08 | -$32.86M derived: sum of 3 quarters · filed 2020-03-03 | -$39.77M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-03-31 | -$11.16M 10-K · filed 2020-03-03 | -$19.20M derived: sum of 2 quarters · filed 2020-03-03 | -$26.11M derived: sum of 3 quarters · filed 2020-03-03 | -$41.84M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2017-12-31 | -$8.04M 10-K · filed 2019-03-19 | -$14.95M derived: sum of 2 quarters · filed 2019-03-19 | -$30.68M derived: sum of 3 quarters · filed 2019-03-19 | -$35.49M 10-K · filed 2020-03-03 | $35.50M 10-Q · filed 2018-08-09 | |||
| 2017-09-30 | -$6.91M 10-K · filed 2019-03-19 | -$22.64M derived: sum of 2 quarters · filed 2019-03-19 | -$27.45M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$15.73M 10-K · filed 2019-03-19 | -$20.54M 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$4.81M 10-K · filed 2019-03-19 | |||||||
| 2016-12-31 | -$9.43M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |